iPS Cells for Disease Modeling

Guest Editors:

Dr. Lezanne Ooi
Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Wollongong, Australia
lezanne@uow.edu.au

Dr. Mirella Dottori
Illawarra Health and Medical Research Institute, School of Medicine, University of Wollongong, Wollongong, Australia
mdottori@uow.edu.au

Deadline for manuscript submissions: closed (30 September 2019)

Message from the Guest Editors

Dear Colleagues,

There is a growing appreciation that the use of human cells in vitro is important for preclinical drug testing and identifying disease mechanisms that can lead to the development of novel therapeutic strategies. The use of induced pluripotent stem cells (iPSCs) for disease modelling and drug discovery has thus exploded over the last decade and almost every disease can be modelled in vitro. Central to the utility of iPSCs is the development of protocols that yield functional disease-relevant cell types that recapitulate disease phenotypes. The aim of this Special Issue is to provide protocols and assays that are used in iPSC disease modelling and to highlight the strengths and weaknesses of the approaches currently available. The articles will be a valuable resource for the disease modelling scientific community.

Dr. Lezanne Ooi
Prof. Mirella Dottori
Guest Editors